ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer.
For questions or additional information, please contact firstname.lastname@example.org.
Interventions of Interest:
- Rucaparib (Rubraca®, Clovis Oncology)
- Niraparib (Zejula®, Tesaro, Inc.)
- Olaparib (Lynparza®, AstraZeneca)
View the Key Stakeholders List.
Below you will find the final documents from the policy paper review process: